- Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck
- NMS Group S.p.A. Appoints Andrew Curtis as Chief Strategy Officer, Effective Immediately
- Nerviano Medical Sciences S.r.l. Expands US Presence
- Nerviano Medical Sciences S.r.l. Announces First Patient Dosed in Phase 1 Clinical Trial of NMS-812 for The Treatment of Relapsed Refractory Multiple Myeloma (MM).
- NMS Group S.p.A. has approved the 2021 Financial Statements with positive outlook for 2022